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ABSTRACT 
 
 
Atrial fibrillation (AF) is the most common arrhythmia, and its prevalcence is 
rapidly rising worldwide, constituting a challenge of both medical and economical 
significance. 
One cornerstone in treating AF is treating atrial fibrillation managing the risk of 
complications, especially thromboembolisim, through use of anticoagulation. 
Another is focused on reducing harm caused by AF while maintaining quality of life 
through either rate control – slowing down the arrhythmia to a managable pace – 
or rhythm control – striving to maintain normal sinus rhythm through medication 
and/or cardioversion, i.e. attempting to restore sinus rhythm either by electrical 
cardioversion or by the use of antiarrhythmic drugs. 
This paper outlines the general course of AF, some of the risk factors and 
treatments with a particular focus on eight antiarrhythmic drugs used in 
pharmacological cardioversion as well as a glance at the data on pharmacological 
cardioversions from the FinCV study. 
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1 Introduction 
Atrial fibrillation (AF) is the most commonly occurring persistent arrhythmia, and the 
prevalence of AF is rapidly increasing.1,2 This has been attributed to multiple factors including 
aging of the population structure as a consequence of increased longevity2, the worldwide 
increase in the prevalence of obesity and sleep apnea3 among others, as well as increased 
awareness and improving diagnostics4. From a public health and cost perspective; it is thus an 
important issue.  
 
The aim of this paper is to review the literature providing a broad overview of the 
epidemiology, mechanism, and treatment of AF, subsequently developing a deeper focus on 
pharmacological cardioversion and finally a brief analysis of the first FinCV dataset with 
regards to factors influencing the success rate of pharmacological cardioversion. 
1.1 Epidemiology and classification 
AF is a supraventricular arrhythmia characterized by unorganized electrical and mechanical 
activity.5 AF prevalence increases clearly with age, with the risk roughly doubling with every 
lived decade6. In a 2014 review of AF epidemiology in Europe, the European AF prevalence 
was  0.12%–0.16% in people under 50, increasing to 3.7%–4.2% in people aged 60–70 and 
eventually 10%–17% in people over 80.2 Population prevalence estimates range from 1.9% to 
2.9% in different European countries2, and 1-5% in various other countries7. The lifetime 
prevalence of AF has been estimated to roughly 25%.6,7 
 
Whether there is an ongoing increase in AF incidence is not as clear. One study noted no or 
only small increases in incidence2, while analysis of data from the long-running Framingham 
Heart Study cohort attributed the increased incidence to better reporting and enhanced 
surveillance4. From a Finnish perspective, an estimated European incidence of 0.23-0.41 new 
AF cases2 per 1,000 person/years equates to roughly 1,300 to 2,300 new cases of AF each 
year in the Finnish population. 
 
In a clinical setting, AF is often primarily classified according to duration. The Finnish Current 
Care Guidelines distinguish between “acute AF” (<48h since onset) and “persisting AF” (>48h 
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since onset).5 The European Society of Cardiology (ESC) outlines the following classification 
and terminology in the 2016 guidelines (Table 1). These definitions are subsequently used in 
this paper. 
 
AF Pattern Definition 
First diagnosed AF 
AF that has not been diagnosed before, irrespective of the duration of the 
arrhythmia or the presence and severity of AF-related symptoms. 
Paroxysmal AF 
Self-terminating, in most cases within 48 hours. AF duration of up to 7 
days. This includes AF that is cardioverted within this time.  
Persistent AF 
AF that lasts longer than 7 days, but less than one year. This includes AF 
that is cardioverted within this time. 
Long-standing persistent AF 
Continuous AF > 1 year, but eventually managed with a rhythm control 
strategy. 
Permanent AF 
AF that is accepted by the patient (and physician). By definition, rhythm 
control is consequently relinquished. 
Table 1 - ESC classification by AF pattern, phrasing slightly simplified.8 
 
Over the course of the disease, typically over many years, AF progresses from 
undiagnosed/symptom-free through paroxysmal AF and persistent AF into 
chronic/permanent AF9,10, shifting back and forth between sinus rhythm (SR) and atrial 
fibrillation either spontaneously or through cardioversion as the disease progresses. 
However, the initial classification is often a misclassification8 and the distinction between 
persistent and permanent AF is sometimes down to the choice of treatment. Thus this 
classification gives an incomplete picture of disease severity and AF burden.11 
 
AF burden, i.e. the share of time the patient on spends in AF compared to SR, is a predictor of 
stroke risk, and it is becoming more evident that also short bursts of AF pose significant risk. 
Using cardiac implanted electrical devices, it has been shown that as little as 5 minutes of AF 
per day increases stroke risk, also in subclinical patients.12-14 
 
However, neither ESC class nor AF burden reflects the symptomatic picture particularly well. 
The modified European Heart and Rhythm Association (EHRA/mEHRA) score8,15 is a better 
measure the partly subjective symptoms of AF. Higher EHRA score is, perhaps not 
surprisingly, associated with both lower quality of life and increased risk of hospitalization, 
but not with mortality.16 Several other scoring systems exist, but their utility is uncertain17, 
and they are outside the scope of this paper.  
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Modified 
EHRA score 
Symptoms Description 
1 None AF does not cause any symptoms 
2a Mild Normal daily activity not affected by symptoms related to AF. 
2b Moderate 
Normal daily activity not affected by symptoms related to AF, 
but patient troubled by the symptoms. 
3 Severe Normal daily activity affected by symptoms related to AF. 
4 Disabling Normal daily activity discontinued. 
Table 2 - The modified EHRA score15 
1.2 Pathophysiology and activation mechanism 
AF can also be classified according to its initiation mechanism. AF typically starts as a 
consequence of repeated atrial extrasystole, often originating close to the pulmonary veins.9 
As the atria are heavily innervated by both sympathetic and parasympathetic ganglia, it is not 
surprising that dysregulation of the autonomic nervous system can contribute to increased AF 
occurrence through several complex mechanisms.18 Increased sympathetic tone, caused by 
e.g. acute stress or exercise, causes increased heart rate and cardiac load, reducing atrial 
refractoriness and initiating AF. It has been shown in several animal models that it is possible 
to inhibit this effect by disrupting the sympathetic innervation or providing low-level 
parasympathetic stimulation.18-20 Conversely, in vagal AF, increased parasympathetic tone 
during rest, sleep or postprandially also leads to reduced atrial refractoriness.18 This is 
common in younger AF patients, where onset of AF occurs during sleep and often resolves a 
few hours later in the morning.21 In animal models, increased AF caused by increased vagal 
tone has been demonstrated in experiments involving both endurance exercise and sleep 
apnea models.18,22,23. This seems to be a significant part of the mechanism through which 
aging endurance athletes tend to develop persistent or permanent AF. 
 
The occurrence of atrial fibrosis has been repeatedly histologically demonstrated in animal 
models of AF, and the consequent changes in endocardial conductivity seem to be playing an 
increasingly significant role. Using increasingly sophisticated electrophysiological mapping 
“baskets”, with 64-252 electrodes and progressively improving algorithms this can now be 
mapped in humans in vivo, as fibrotic areas display reduced electric conductivity and lines 
lacking electric conductivity. This has increasingly demonstrated two different sustaining 
mechanisms in AF: areas of rotating activation (“rotors”) and ectopic focal activation (“foci”).9  
Increased duration of AF has been linked to an increased number of rotors and foci, as well as 
differences in the distribution of these areas. This progressively more detailed picture of the 
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electrophysiological mechanisms in AF has been utilized in the development of more effective 
ablation techniques, but the results are still somewhat contradictory.9,24,25 
2 Management of AF 
The clinical management of AF can grossly be divided into three parts:  
 Management of risk factors - prevention of occurrence or recurrence of AF. 
 Management of risk of sequelae – anticoagulation 
 Management of the arrhythmia - rhythm and/or rate control. 
2.1 Manageable risk factors  
Many of the risk factors for AF are not manageable, e.g. age, sex and familial/genetic factors, 
and age and sex are the strongest predictors of AF, as every decade roughly doubles the risk of 
developing AF, and males have a 50% higher lifetime risk6. Variants in both ion-channel and 
non-ion-channel genes have been linked to AF, otherwise mostly considered a sporadic, non-
genetic disorder.26  
 
However, many risk factors for AF are very manageable. These are often closely related to 
lifestyle, including obesity, hypertension, diabetes, sleep apnea, sustained endurance exercise 
and the consumption of alcohol and tobacco. The following points denote some of the key 
features of these risk factors. It is prudent to note that this is not an exhaustive list of 
established risk factors, and evidence for others is continuously accumulating. 
 
 Obesity increases AF through increased cardiac load as well as several of the factors 
listed below. It is associated with a hazard ratio of 1.39-1.75 already at BMI 25-30 and 
1.99-2.35 at BMI over 30.6 At every step BMI increases, the risk of AF increases by 3-
7%, depending on duration.27 A weight reduction of >10% was associated with a 6-fold 
increase in arrhythmia-free survival compared to lesser weight loss in one study.28 
 Diabetes is associated with risk ratio of 1.4-1.6 for AF.6 While many risk factors are 
shared, diabetes is an independent risk factor for AF, where longer disease duration 
and worse glycemic control increase the risk of AF.29 
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 Hypertension is a well-documented, common but relatively modest risk factor for AF, 
with a risk ratio of 1.2-1.5.6,30 This risk seems to be reversible, as one study designed to 
lower blood pressure through renal sympathetic denervation demonstrated the 
reversibility of fibrosis, reduced ventricular mass as well as improved atrial 
conduction. It is however unclear whether part of this effect was due to direct effects of 
the renal denervation.31 
 Extensive endurance training is a known risk factor particularly in lone AF, i.e. the 
occurrence of AF without significant comorbidity. One study found a threshold of a 
cumulative 1,500 hours of sport practice32, a surprisingly low number considering that 
it entails a significant risk of developing AF (HR = 2.87). A study of exercise habits in 
the elderly found that moderate but not vigorous exercise decreased incidence of AF 
by 28% compared to no exercise.33 
 Obstructive sleep apnea (OSA) and AF share many risk factors (obesity, alcohol 
overconsumption, autonomic dysregulation, diabetes) but OSA is an independent risk 
factor for AF, with an approximately 4-fold risk of developing AF.6,34 Along with weight 
loss, CPAP remains the gold standard treatment for OSA, and has additionally been 
shown to decrease AF recurrence after catheter ablation.35 
 While heavy drinking is a well-documented risk factor for atrial fibrillation, with a HR 
of 1.34 to 1.46 for new-onset AF6,36, there seems to be considerable individual 
variability in the arrhythmogenic effect of alcohol. Moderate consumption seems to 
have very little effect on AF, while heavy consumption is associated with increased AF 
at least in men. “Holiday heart”, i.e. AF associated with binge drinking and/or 
withdrawal has been speculated to be due to increased noradrenergic activation as 
well as decreased vagal activation.6 Sobering up often restores sinus rhythm without 
(other) intervention. 
 Tobacco consumption is associated with a significant increase in AF risk. Specifically, a 
smoker has a hazard ratio of 1.51–2.05 compared to a never-smoker, and a former 
smoker somewhat less. The risk seems to be dose-dependent.6,37,38 
2.2 Anticoagulation treatment 
Oral anticoagulation (OAC) is the keystone treatment for managing the risk of 
thromboembolic complications (TEC), as AF is present in at least 20-25% of stroke patients 
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and stroke risk in AF patients is twice that of those in sinus rhythm.5 Several significant 
changes have occurred in OAC in the recent years, among others the widespread use of new 
oral anticoagulants (NOAC) and the increased awareness of periprocedural TEC risk in 
cardioversion.  
The 2017 Finnish Current Care Guidelines (CCG) recommend The CHA2DS2-VASc score for 
evaluating the risk of TEC; albeit with a slight modification - female sex adds one point only 
over the age of 75 in the Finnish version of the score. Thus the scoring system and cut-offs 
differ from the ESC guidelines, as the Finnish guidelines use the same cut-offs for both sexes.5,8 
Factor Score 
 C   Congestive heart failure (signs/symptoms or reduced LVEF) 1 
 H  Hypertension: RR >140/90 mmHg at rest repeatedly (or medication) 1 
 A2  Age ≥75years 2 
 D  Diabetes (fasting glucose >7 mmol/L or medication) 1 
 S2  Stroke or TIA or other thromboembolism 2 
 V  Vascular disease (ASO, MCC, vascular dementia etc.) 1 
 A  Age, 65–74 years 1 
 Sc  Sex category (female, counts only if  age over 75) 1 
Table 3 – Modified CHA2DS2-VASc score recommended by the Finnish CCG5 
The Finnish CCG recommends OAC for patients with high risk for TEC, i.e. CHA2DS2-VASc ≥ 2, 
with an NNT of < 85, or even < 15 at CHA2DS2-VASc scores of 3 or higher.5 For patients with 
CHA2DS2-VASc = 1, the CCG recommends individual assessment of the risks and benefits of 
OAC, including bleeding risk and thromboembolism risk factors not included in the CHA2DS2-
VASc, e.g. smoking39, dyslipidemia5 and renal dysfunction40,41. For patients with CHA2DS2-
VASc = 0, no anticoagulation is recommended. Acetyl salicylic acid is not recommended for 
stroke prevention in AF at any risk level, as it inefficient in stroke prevention but increases 
bleeding risk significantly, at levels comparable to warfarin.5,8  
The HAS-BLED score, published in 201042, is a useful predictor of bleeding risk, see table 4. 
Patients with a high HAS-BLED score, particularly if they score higher on HAS-BLED than 
CHA2DS2-VASc, require a careful evaluation of the risks and benefits of oral anticoagulation.5 
However, most of the risk factors for bleeding, can be managed and reduced, and seldom pose 
a greater risk than the lack of anticoagulation, even in the elderly and frail.5,43 
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Factor Score 
 H   Hypertension, i.e. >160 mmHg systolic blood pressure 1 
 A 
Abnormal renal function, severe OR 
Abnormal liver function, severe 
1 + 1 
 S  Stroke 1 
 B  Bleeding risk, e.g. anemia, thrombocytopenia, bleeding history, cancer 1 
 L  Labile INR, i.e. TTR < 60% 1 
 E  Elderly, i.e.  age over 65 years 1 
 D 
Drug or alcohol usage history (≥ 8 drinks/week) OR 
Medication predisposing to bleeding (NSAID etc.) 
1 + 1 
Table 4 – The HAS-BLED bleeding risk scale42 
Anticoagulation is well supported in cardioversion (CV) of AF with duration >48 h, requiring 
NOAC or warfarin at therapeutic levels for 3 weeks before elective CV, and continuing for at 
least one month after CV.5 However, the 2010 (and the 2012 update) ESC guidelines still 
considered cardioversion of acute AF (duration <48h) without previous anticoagulation 
acceptably safe in all patients, using only unfractionated or low molecular weight heparin 
perioperatively.44,45 Post-CV OAC was considered based on CHA2DS2-VASc score, as outlined 
previously.  However, in 2013 the FinCV study demonstrated a heightened stroke risk after CV 
of acute AF, with a 0,7% rate of TEC within 30 days after CV. The vast majority of the 38 TEC 
were TIA (n=4) or stroke (n=31). The median and mean interval between CV and TEC were 2 
and 4.6 days respectively, pointing at a clearly increased risk in the days following CV, 
particularly in several identified subgroups. The difference in risk between electrical and 
pharmacological cardioversion was insignificant (p=0.32).46 The FinCV study also 
demonstrated that CV without anticoagulation within 12 hours of onset of AF is significantly 
safer than CV in the 12-24 and 24-48 hour windows, with OR of 4.0 and 3.3 respectively.47 
The Finnish CCG points to using the CHA2DS2-VASc score for evaluating TEC risk in CV of acute 
AF, suggesting that in low and medium risk patients (CHA2DS2-VASc 0-1) no pre- or post-CV 
anticoagulation is necessary, while in high-risk patients (CHA2DS2-VASc ≥ 2) NOAC or 
warfarin + LMWH should be started before CV.5 The 2016 ESC guidelines have very little to 
say about the anticoagulation of acute AF, noting the need for further research whether there 
is a “safe” window for CV.8 The 2019 update to the American Heart Association’s 
recommendation for AF similarly points this out that the evidence for the safety of CV of acute 
AF without anticoagulation is limited.48 
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A decent treatise of NOACs is outside the scope of this paper, but in brief: dabigatran, 
rivaroxaban, edoxaban and apixaban have progressively revolutionized anticoagulation, and 
are as safe as or safer than warfarin, despite several of these lacking direct antidotes, and as 
efficient or better in preventing TEC.8,49 
2.3 Management of arrhythmia - rhythm vs. rate control 
Six key points for long-term pharmacological treatment of AF were outlined in the 2010 ESC 
guidelines: Treatment should aim to reduce symptoms and success may mean to reduce 
rather than eliminate recurrence of paroxysmal AF, efficacy of antiarrhythmic drugs (AAD) is 
limited, and if one fails another may be more successful. Pro-arrhythmic side-effects are 
common and safety should be considered the primary guiding factor, rather than efficacy 
alone.8,44 These are still relevant to pharmacological treatment pursuing both rhythm and rate 
control, and largely applicable to short-term treatment and pharmacological CV. 
Rate control, i.e. accepting AF and focusing therapy on minimizing the negative effects and 
risks of AF, aims to maintain left ventricular function, cardiac output and quality of life while 
reducing symptoms and tachycardiomyopathic effects. Rate control should be considered the 
primary strategy for the elderly and asymptomatic patients, as it has been shown to be non-
inferior.8,50 
Rhythm control is a broad concept. It includes pursuing sinus rhythm by medication, CV and 
electrophysiological or surgical intervention. Counterintuitively, there is no convincing 
evidence to suggest that active rhythm control would improve long term outcomes.8 
Preliminary results from the recent CABANA trial seem to close another open question, 
indicating that catheter ablation offers no significant advantages over optimal medication, i.e. 
no reduction in risk of death, disabling stroke, serious bleeding, or cardiac arrest.51,52 
However, rhythm control is still suggested in the following patient groups: 8,15,50 
1) Symptomatic patients, i.e. a modified EHRA score of 2b or higher. 
2) Patients with heart failure where AF increases symptoms 
3) Young patients, at least as an initial approach when invasive treatment has not been 
ruled out, as prolonged AF before ablation may reduce chances of ablation success. 
4) Secondary AF, e.g. in hyperparathyroidism and ischemia. 
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2.4 Classification and mechanisms of antiarrhythmic drugs 
Miles Vaughan Williams originally proposed a four-part classification of antiarrhythmic drugs 
in 1970 and added the subdivision of class 1 into 3 subclasses in 1984.53 While newer systems 
of classification have been proposed54, the Vaughan Williams classification is still stands at the 
core of it, and as such is worth a short consideration regarding the antiarrhythmic drugs 
available in Finland. 
However, as our understanding of the molecular mechanisms of the action potential and 
plethora of variants that exist among ion channels has increased dramatically since the days 
of Vaughan Williams, this short treatise is bound to be a simplification, as delving into the 
details of the various receptor affinities of each drug is outside the scope of this text. The 
comprehensively updated and expanded classification proposed by Lei et al in 2018 is worth 
looking into for further details and references.54 
Class 1 consists of drugs inhibiting voltage gated sodium ion channels, reducing maximum 
rate of depolarization. Based on their differing dissociation rates, these drugs are further 
subdivided into classes 1a (intermediate dissociation kinetics), 1b (fast dissociation kinetics) 
and 1c (slow dissociation kinetics), which partly account for their different profiles. 
Class 1a drugs include quinidine and disopyramide, both of which are still available by special 
permission (“erityislupavalmiste”). While these had some utility in the prevention of 
recurrence of AF8,55, increased mortality (up to twofold in quinidine56) in patients with 
coronary heart disease and heart failure, significant pro-arrhythmic effects (Torsades de 
Pointes) and the availability of safer options have all but eliminated their usage significantly 
in the last decade. 
Class 1b is best known for lidocaine, which indeed has a place alongside amiodarone in the 
management of acute ventricular arrhythmias. However, it lacks any significant efficacy in 
cardioverting AF, as in one study none of twenty AF patients administered lidocaine 
converted to sinus rhythm (CI 0-14%)57. 
Class 1c is the newest group, of which flecainide and propafenone are available in Finland, 
although propafenone only by special permission. Flecainide is commonly used both for 
pharmacological CV and rhythm control, and propafenone is pharmacodynamically rather 
similar but with a greater variability in pharmacokinetics. Both have significant 
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proarrhythmic effects due to a paradoxical increase in ventricular rate due to faster AV nodal 
conduction and/or conversion to 1:1 flutter, and both are contraindicated in patients with 
previous ischemic heart disease, myocardial infarction and/or heart failure. 5,56 
Class 2 consists of drugs affecting the sympathetic nervous system, in newer classifications on 
both the sympathetic and parasympathetic side54, some of which are under development. In 
practice, the drugs that are currently clinically available in Finland are beta blockers with 
their varying pharmacodynamics- and kinetics, metoprolol and bisoprolol being the most 
commonly used58. 
Class 3 consists of drugs prolonging repolarization by blocking voltage gated potassium ion 
channels, and these are rather diverse. Dofetilide is the rare example of a “pure” potassium 
channel blocker, but not available in Europe, however, the closely related drug ibutilide is 
occasionally used for  pharmacological CV or drug-assisted ECV in AF resistant to ECV. 
Amiodarone, useful for both CV and maintaining sinus rhythm, possesses traits from all of 
classes 1-4. Dronedarone is an amiodarone analogue, but does not contain iodine and has a 
somewhat different profile. Sotalol, a beta blocker, also exhibits class 3 effects at higher doses 
and is sometimes classified as class 3.8,54 
Class 4 consists of the non-dihydropyridine calcium ion channel blockers, in Finland diltiazem 
and verapamil. While these have some utility in rate control, neither verapamil nor diltiazem 
have been shown to be efficient in  pharmacological CV or enhancing electrical cardioversion 
(ECV) probability.8,59,60 
Additionally, several drugs do not conform clearly to any of the classical classes, as they have 
different mechanisms: digoxin and vernakalant are two that are relevant in AF and are 
discussed separately in the next section.  
Adenosine, mostly utilized in CV of non-AF supraventricular tachycardia, activates G-protein 
coupled receptors, which through K-channel activation shortens the action potential, causes 
hyperpolarization and reduces automaticity, thus often terminating the tachycardia.56 While 
adenosine may have a place during electrophysiological examinations, there seems to be no 
indication that adenosine would be effective in CV of AF. 
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3 Electrical cardioversion 
Synchronized biphasic ECV  with anterior-posterior electrode placement is the gold standard 
of comparison for restoration of sinus rhythm in acute AF8, with a success rate typically in 
excess of 90 %, in one study 94% when including all AF durations (n=88)61. It is the only 
useful method of CV in persistent or permanent AF, as pharmacological CV quickly loses its 
efficacy as AF is prolonged.5,8 While immediate cardioversion is indicated in hemodynamically 
unstable AF patients in order to restore cardiac output, regardless of the conventional 
contraindications previously outlined8,50, ECV in stable patients should only be undertaken 
without anticoagulation if a thrombus can be ruled out by transesophageal 
echocardiography62,63. If ECV is performed on non-acute AF without anticoagulation, the risk 
for thromboembolism is significant, 5-7%5,64,65. 
The major drawback for elective ECV is the requirement of anesthesia, and thus also an 
anesthesiologist or other physician sufficiently proficient in anesthesia. Thus, CVs are 
concentrated to hospital settings for patient safety. Additionally, a 4 hour period of fasting is 
required before anesthesia, although ECV can be performed following rapid sequence 
induction and intubation if hemodynamically necessary. Anesthesia is commonly performed 
with propofol, although midazolam and others may also be used. With propofol, the two most 
common anesthesia complications are apnea, requiring ventilation, and hypotension, 
occasionally requiring vasoactive agents such as etilefrine.66 Significant electrical burns are 
very rare, but mild burns occasionally occur.  
Non-transient asystole and/or bradycardia is rare, 0,9% in the FinCV study, but may require 
resuscitation, chronotropic medication and/or external pacing, and is often indicative of a 
problem in the sinoatrial node, with slightly less than half of these patients eventually getting 
a pacemaker.67 
4 Pharmacological cardioversion 
Pharmacological CV, by definition, is the restoration of sinus rhythm by the use of 
antiarrhythmic drugs, i.e. a form of acute rhythm control. The obvious advantage is the lack of 
need for anesthesia and pre-intervention fasting, thus allowing for a greater availability and 
flexibility of use outside of hospital settings. The clearest limitation, on the other hand, is the 
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somewhat lower efficacy of pharmacological CV compared to ECV, as well as the 
contraindications and side effects of the drugs used. As with the treatment of all AF, 
electrolyte levels should be checked before CV, and adequate hydration levels ensured to 
avoid unnecessary complications. 
The following sections will outline the efficacy, benefits, indications and contraindications of 
the antiarrhythmic drugs used for rhythm control of AF in Finland. 
4.1 Beta blockers 
In primary and first aid/emergency care settings, beta blockers tend to be the first drug 
administered to patients with acute AF, often in the form of intravenous metoprolol, or 
sometimes oral bisoprolol or metoprolol, since these are well tolerated with few side effects. 
While there are significant variations across patients regarding the negative inotropic and 
chronotropic effects of beta blockers, sharp declines in maximum cardiac output is rare at 
therapeutic doses. However, significant decompensation is a contraindication, as additional 
reduction in cardiac output can cause hemodynamic crashing.56,68 On the other hand, 
tachycardic patients with relatively mild hypotension usually tolerate beta blockers well, in 
part due to the fact that at reduced heart rate improves ventricular ejection fraction. 
Bradycardia, advanced peripheral artery disease and conduction abnormalities (e.g. 
atrioventricular block gr. II and III, sick sinus syndrome) are stricter contraindications, as beta 
blockers may exacerbate these conditions. Asthma and diabetes similarly warrant awareness 
of the potential side effects, but significant adverse events are rare.68 
While beta blockers do have the advantage of slowing the AF to a pace that is more 
economical, there is no evidence that beta blockers would possess any significant efficacy as 
pharmacological CV drugs or ECV enhancers compared to placebo.8,69 However, as beta 
blockers are so commonly administered and a significant portion of AF cases self-terminate, a 
misappropriation of clear causality seems to be quite common, both among patients utilizing a 
pill-in-the-pocket beta blocker approach as well as some physicians. 
Ultrashort-acting beta blockers have, however, been suggested for CV. In a Japanese review, a 
CV success rate of 50-75% with landiolol was noted.70 This was, however in an ICU setting, 
and does not offer any clear conclusions for usage outside the ICU. 
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Sotalol, a beta blocker, is often grouped among class 3, as it exhibits group 3 properties at 
higher doses. Curiously, sotalol is racemic mixture of two stereoisomers, of which l-sotalol is 
mainly responsible for the beta-blocking while d-sotalol provides the class III properties. 
Among beta blockers, sotalol has the rare property of being pro-arrhythmic, with TdP 
incidence commonly cited at 2-4%. However, a recent review points out that TdP becomes 
significantly rarer as long as prolonged QT-interval and EF < 35% is considered as 
contraindications, citing incidences as low as 0,1%.71 In another systematic review, sotalol 
was found to be as effective as class 1a, 1c and amiodarone in CV of AF, and only high dose 
ibutilide to be more effective.72 With a linear pharmacokinetic profile, rapid onset, and good 
efficacy, sotalol could provide a viable alternative both for CV as well as use in other niches 
such as AF prevention after coronary bypass.71 
4.2 Digoxin 
Cardiac glycosides had been utilized for several centuries before in 1785, William Withering 
published his findings regarding digitalis and its usefulness in dropsy, i.e. peripheral edema 
seen in heart failure. By trial and observation, Withering learned to dose digitalis to obtain 
diuresis but avoid excessive toxicity.73 
The pharmacodynamics- and kinetics of modern digoxin, the active ingredient of Digitalis 
lanata, are complex. Digoxin acts as both an inhibitor of myocardial Na+/K+ ATPase, which 
leads to an increased level of intracellular calcium, causing a positive inotropic effect56, giving 
it its unique position as the only inotrope currently in outpatient usage, a valuable tool for 
treating heart failure. 
Additionally digoxin increases parasympathetic activity on several levels, among these 
activating CNS vagal centers and by increasing baroreceptor sensitivity. The overall effect is 
negatively chronotropic through hyperpolarization and increased refractory of myocytes as 
well as slowed AV-node conduction.54,56 These effects give digoxin it useful properties for rate 
control, although it should be noted that AV-block may also occur, and 2° and 3° AV-block is a 
contraindication, as is hypertrophic obstructive cardiomyopathy and Wolff-Parkinson-White 
syndrome.68 
As oral digoxin reaches its steady state concentrations slowly over approximately a week, 
digitalization per os is slow. In an acute situation, rapid digitalization can be achieved in a few 
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hours using intravenous administration, with individualized starting doses of 250-1000ug. 
Follow-up and digoxin concentration monitoring is essential, as digoxin toxicity increases 
rapidly at plasma concentrations above 1,5 ng/ml, not much above the therapeutic upper 
limit. Symptoms include general malaise and a variety of arrhythmias, and renal insufficiency 
and hypokalemia are among the most common risk factors.56,68 Besides cessation of 
medication, treatment may include iv potassium, magnesium, atropine or lidocaine for 
arrhythmias as well as specific antibodies.56,68 
While digoxin is commonly used as the second drug of choice in primary care, as it is readily 
available, it is suitable for use only when the primary goal is not immediate CV, as digoxin has 
not been shown to be useful in pharmacological CV or in enhancing ECV success likelihood.8,74  
4.3 Flecainide 
Flecainide is, despite its contraindications and side effects, well suited for CV, particularly as it 
is available and effective not only intravenously but also orally.  
When choosing which AAD to ordinate, the essential question eventually becomes, which drug 
is the best one in which situation? A 2012 meta-analysis by Bash et al, analyzing 2433 
patients75 can begin to shed light on this, as this analysis compared the efficacy of several 
AAD:s for CV of acute AF (<48h) within two timeframes: 0-2 hours and cumulatively 8-24 
hours after drug administration: 
Treatment n CV rate by 2 h CV rate 8-24 h 
Placebo 583 11.8 % 48.2 % 
Flecainide - oral 40 67.5 % 80.6 % 
Flecainide - IV 234 63.7 % 69.9 % 
Propafenone - Oral 326 21.2 % 78.7 % 
Propafenone - IV 301 50.8 % 81.9 % 
Amiodarone - Oral 43 9.3 % 87.1 % 
Amiodarone - IV 266 16.2 % 61.2 % 
Vernakalant - IV 365 51.8 % N/A 
Table 5 – Acute AF CV rates from 2433 patients75 
Table 5 contains many worthwhile observations, the first of which is that the placebo CV rate 
by 24 hours is a stunning 48 % (n=583), but only 12 % by the 2 hour mark, raising an 
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interesting question in whether CV should be attempted at all before the 24-hour mark, in 
order to avoid unnecessary interventions in stable patients with acute AF? Then again, the 
increased risk of TEC after the 12 hour mark indicates that sooner seems to be better than 
later.47 
Along this line of reasoning, short time to CV is one hallmark of a good CV drug, and flecainide 
certainly makes the mark, with 64% (iv) and 68 % (oral) CV rates respectively within the 2 
hour window, making it significantly faster, with very credible OR of 9.63 (95% CrI 2.38–
36.26) and 11.43 (95% CrI, 1.29–99.12) respectively. Oral flecainide achieves significance also 
at 8-24 hours with OR 6.53 (95% CrI 1.24–39.58), while IV flecainide does not. Similar results 
have been noted in another review.76 
Although efficacy definitely backs flecainide as a good choice for pharmacological CV, previous 
myocardial infarction is a strict contraindications due to increased mortality demonstrated in 
long-term use77, however, in mild ischemic heart disease the use of flecainide is considered 
acceptable56. Heart failure is another contraindication, as proarrhythmia tends to manifest 
mostly in patients with structural heart disease56, although besides this a mild negative 
inotropic effect has also been demonstrated in healthy patients78. As flecainide may 
paradoxically increase ventricular rate due to faster AV nodal conduction and/or conversion 
to 1:1 flutter, pre-administration with a beta blocker is highly recommended and atrial flutter 
is naturally a contraindication. As flecainide sometimes causes post-CV bradycardia, 2° and 3° 
AV-block, abnormal sinus node function and widened QRS complex, whether due branch 
blocks or otherwise, are also contraindications.5,56 However, it is possible to use flecainide to 
treat acute AF associated with WPW, as flecainide slows conduction through accessory 
pathways as well.5 Care is required in patients with severe hepatic or renal insufficiency.68 
Flecainide is an effective way to prevent recurrent AF, but regular ECG monitoring for signs of 
TdP is recommended at baseline and daily during days 1-3 of flecainide use. This protocol is 
recommended for propafenone and sotalol as well.8 Once safety has been established, 
flecainide can be used for pill-in-the-pocket patient-controlled CV. One study found that this 
approach had a success rate of 94% and very limited adverse events, concluding that this 
method of CV is acceptably safe.79 
Finally, when all else is equal, flecainide has the benefit of being cheap – a single dose of 
300mg flecainide currently costs less than 2€, while another popular method for CV, IV 
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vernakalant, which currently costs 510€ per dose.68 The difference will inescapably add up 
over time. 
4.4 Propafenone 
While the CV efficacy of propafenone is at least on the same level as flecainide, albeit perhaps 
a bit slower75 – see table 5 above - propafenone offers few if any clear advantages over 
flecainide, except for being another option to try in case flecainide causes deal breaking non-
cardiac side effects. 
On the downside, propafenone comes with all the challenges and contraindications of 
flecainide, with the addition of more variation in pharmacokintetics56, and the need to reduce 
doses already in mild and moderate hepatic insufficiency. To top it off, propafenone is no 
longer available without special permission.68 All in all, flecainide is the go-to class 1c drug, 
and propafenone a second option. 
4.5 Amiodarone 
Amiodarone is usually classified as a class III AAD, and can be more specifically described as a 
non-selective blocker of voltage dependent potassium channels, prolonging refractory time, 
action potential recovery time and decreasing re-entrant tendency, as well as other effects 
mimicking the other AAD classes.54 While Amiodarone comes with clear drawbacks in other 
areas, its main advantage is that it may be used also in unstable patients with significant 
structural or ischemic heart disease including acute myocardial infarction8, even when 
ejection fraction is severely reduced, although most studies tend to exclude patients with 
severe heart failure.8,80 Amiodarone has almost no negative inotropic effect, a clear advantage 
compared to class 1c drugs,56 although cases of worsening heart failure have also been 
reported with amiodarone as well. CV success rate varies, coming in at 34-95% depending on 
dose, treatment regimen (iv bolus vs infusion) and patient subgroup.81 
Due to its slower pharmacokinetics, in comparison to flecainide, amiodarone infusion is 
slower and the efficacy of amiodarone is inferior up to 8 hours after initiation of treatment, 
but similar at 24 hours after initiation of treatment.75,82 Lengthening of QTc is a quite frequent 
side effect, but subsequent proarrhythmic adverse events are quite rare.5,68 
 
17 
 
 
 
Long-term use of amiodarone comes with significant risks of extracardiac complications, and 
although these are rare in short-term usage for CV56, acute complications do occasionally 
occur also in as little as 24 hours68. As amiodarone is potentially highly pneumotoxic, initial 
chest x-ray is mandatory and spirometry highly recommended if time allows. If the patient 
displays respiratory symptoms during or after amiodarone usage, repeat X-ray or computed 
tomography, spirometry and diffusion capacity testing are warranted, as well as cessation of 
amiodarone. Resulting interstitial pneumonitis is often reversible, but fatal cases have also 
occurred. Similarly, amiodarone is hepatotoxic, and monitoring of transaminase levels is 
warranted. Acute liver toxicity within 24 hours of starting amiodarone infusion has been 
reported, and adequate initial follow-up is required. Amiodarone occasionally causes 
iatrogenic thyreotoxicosis, wherefore initial evaluation and follow-up of TSH, T4v and T3v is 
needed.5,8,68  
Outpatient follow-up of ECG, ALAT, ASAT, AFOS, bilirubin, TSH, T4v, T3v, Na, K and creatinine 
/ GFR, is recommended at 3, 6 and 12 months after initiation and annually thereafter, and 
spirometry and chest x-ray if needed.56 Amiodarone also has significant interactions with 
many drugs, including warfarin, dabigatran, class 1a, 1c other class III and class IV AADs, 
several antipsychotics, antidepressants, antibiotics and antimalarial drugs.68 Although beta 
blockers may cause additional negative inotropic balance, a small dose of beta blockers is 
generally recommended alongside amiodarone for prevention of pro-arrhtythmia.56 
Due to its plethora of possible adverse effects and interactions, long-time treatment with 
amiodarone is not a first-line treatment but practically the drug of choice where class 1c is 
contraindicated and beta- and calcium channel blockers insufficient.80 Whenever possible, 
after a steady state dose and effect has been established, it is prudent to strive to use as low a 
dose as possible. As noted previously, sotalol may in light of a recent review be a worthwhile 
alternative71, although some studies have found sotalol to be an inferior alternative to 
amiodarone for CV and recurrence prevention8,83. 
4.6 Dronedarone 
To the best of my knowledge, data on the efficacy of dronedarone used as a pharmacological 
CV drug have not been published, nor has any conclusive data on whether dronedarone might 
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enhance ECV success rates. However, as an amiodarone analogue, it is worth a brief 
consideration for its role in AF recurrence prevention. 
Like amiodarone, its several decades newer sibling dronedarone possesses traits from all AAD 
classes, but displays several important differences. One mixed treatment comparison 
indicates that in long term use, although not quite as good as amiodarone for sinus rhythm 
retention, dronedarone is associated with to fewer serious adverse and proarrhythmic events 
than other AADs including amiodarone.84 
As dronedarone, unlike amiodarone, does not contain iodine, it has significantly less thyroid 
complications than amiodarone. However, dronedarone is contraindicated in heart failure 
(increases mortality) and permanent AF (increases mortality), and thus its usage more limited 
than that of amiodarone. Additionally, toxic reactions to the liver or lungs from amiodarone 
also constitute contraindications.  Liver toxicity seems to be more common than in 
amiodarone, and monthly transaminase monitoring is warranted during the first 6 months of 
use, and at regular intervals after that.5,8,68  
In summary, careful patient selection and proper monitoring by a cardiologist is key to 
commencing dronedarone successfully, and dronedarone reduces AF-related hospital visits8. 
However, if and when AF becomes chronic, dronedarone should be terminated.5,68 
4.7 Ibutilide 
The capabilities of ibutilide, a quite pure potassium ion channel blocker, are well documented 
both when used as a CV drug and as an ECV enhancer.85-88, It is a particularly effective drug 
when it comes to atrial flutter, which otherwise tends to be more treatment-resistant than AF. 
CV success rates have been reported at 31-61.5% in AF and 63-90% in atrial flutter. 85-87 
The most common side effect is proarrhythmia, which relegates ibutilide to be used by 
specialists well familiar with it. TdP occurs quite frequently, cited as high as 4-8% of CVs in 
one evidence review, along with other arrhythmias as well, occasionally persisting long 
enough to warrant electric CV87. Cardioversion with ibutilide is generally very fast, with a 
mean time to sinus rhythm at 27 min (n=266), and pro-arrhythmic complications tend to 
develop within a similar timeframe.86 If CV does not succeed within 1 hour of ibutilide 
administration, ECV may be performed.68 
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Ibutilide can also be used to aid ECV if ECV at maximum energy fails, and the infusion can be 
performed under the same anesthesia. This is particularly helpful in case of ECV resistant 
atrial flutter.  
While it is effective, it should be noted that ibutilide is contraindicated in 2° and 3° AV block, 
sick sinus syndrome, even marginally prolonged QTc (>440ms) and bradycardia below 
50/min.5,8,68 
It is worth noting that ibutilide is currently the most expensive drug reviewed, as a single 
adult dose currently costs 598€, and two doses may be used if the first fails to produce sinus 
rhythm within 10 minutes.68 
4.8 Vernakalant 
Vernakalant is the most recently released AAD on the Finnish market, released close to 10 
years ago. When it was released, it was marketed as a fast, safe replacement for ECV, and has 
admittedly lived up to its promises quite well. The efficacy in short-duration AF (<72h) is 
good, with CV occurring in 61% of patients in one trial, and 53% retaining normal rhythm at 
60 minutes after administration the first dose of vernakalant infusion.89 
Efficacy decreases clearly the longer the AF duration is, as was clearly shown in one study 
demonstrating a 52% vernakalant CV efficacy with AF of 3 hour to 7 day duration (n=145) 
and 11% efficacy with 8 to 45 day AF duration (n=75).90 One Finnish study found vernakalant 
to be more effective than iv flecainide at 120 min post-administration (63% vs 47% PCV rate, 
n=200, p=0,00IV91, although as has been noted earlier, oral flecainide seems to display a 
higher efficacy. Unfortunately, vernakalant is no better than placebo for atrial flutter.92 
Pharmacodynamically vernakalant is different from most other AADs, as its effect seems to be 
primarily based on blocking ultrarapid potassium ion channels, which are primarily 
expressed in the atria but not in the ventricles. This, along with several other effects of 
vernakalant, increases in action potential recovery time and refractory period while reducing 
reentrant tendency.8,54,56 
Vernakalant has few side effects. By 2014, the only documented vernakalant-related case of 
TdP occurred in a patient that accidentally received both ibutilide and vernakalant92, 
suggesting that vernakalant does not cause TdP. Side effects of vernakalant include temporary 
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disturbances of taste, sneezing, bradycardia and hypotension, the latter two of which are also 
contraindications. Other contraindications are moderate to severe heart failure,  (NYHA III-
IV), 2° and 3° AV block, severe aortic stenosis, QTc >440 ms, acute coronary syndromes within 
30 days and previous administration of class 1 or 3 AADs within at least 4 hours.8,56,68 
5 The FinCV Study 
5.1 Methods 
The Finnish Cardioversion - FinCV - study (ClinicalTrials.gov Identifier: NCT013805793) is a 
multicenter retrospective study primarily investigating the incidence of thromboembolic 
complications within 31 days of cardioversion. All adults diagnosed with AF or atrial flutter in 
two university hospitals and one secondary hospital between 2003 and 2010 were included. 
Extensive data was gathered on each included patient, including CHA2DS2-VASc and HAS-
BLED scores. The usage of a multitude of AADs and anticoagulants at CV as well as when the 
patient was discharged were recorded. In total, 7728 events were recorded from a total of 
3181 patients. 
From a pharmacological CV perspective, this dataset is problematic, as it did not record 
whether CV was primarily intended to be pharmacological or whether it was always intended 
to be electrical, and thus it is not possible to draw clear conclusions regarding the efficacy of 
AADs, as an attempted CV that does not produce sinus rhythm within a few hours in the 
emergency room easily turns into an ECV due to either medical or logistical reasons, and is 
thus recorded as an ECV. Conversely, the same drug may also be part of the patient’s regular 
medication thus recorded as medication used at ECV, or the patient may return to sinus 
rhythm spontaneously  without any extra doses of AADs. 
Naturally, AADs used only for CV such as ibutilide and vernakalant would be clear-cut cases, 
however, neither of these were included in the dataset. As this is a clear methodological 
limitation, no further analysis attempting to ascertain whether there are significant 
differences in pharmacological and electrical CV efficacy in this dataset will be attempted, but 
some descriptive statistics may still provide insight. 
Analysis was performed with SAS JMP 13.1. and Excel 2010 for Windows. 
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5.2 Results and discussion 
In this dataset, just 753 CVs, (9,7%) were recorded as non-electrical, i.e. pharmacological. Of 
these, the most commonly recorded drug was flecainide, mostly with a beta blocker or as 
monotherapy, followed by beta blocker monotherapy and no medication, which is essentially 
just spontaneous termination of AF. Arguably, in the light of the literature, the same can be 
said of the patients with no medication noted. All other AADs had frequencies under 10, 
propafenone, a well-established AAD effective in CV had as little as two cases. Recorded CV 
success rates in the data set ranged from 91-100%, clearly indicating a selection bias. 
 
 n 
Share of 
Pharmacological CV 
events 
Flecainide total 527 69,72 % 
Flecainide and BB 408 54,18 % 
Flecainide only 72 9,56 % 
   
Beta blocker only 114 15,14 % 
   
No medication noted 79 10,49 % 
   
Amiodarone total 20 2,66 % 
Amiodarone and BB 15 1,99 % 
   
Others 13 1,99 % 
Total 753 100% 
 
Table 6: Frequency table of select PCV drugs 
One can attempt to assume that if an AAD is used at CV but not at patient discharge, it was 
intended for pharmacological CV. Under this assumption we can observe a 60% CV success 
rate using flecainide, a result comparable to the literature mentioned in section 5.3., though it 
should be noted that this assumes that all ECVs done in the presence of flecainide are failed 
CVs, which probably an overestimation.  
 n (% total) ECV failure ECV success PCV failure PCV success 
Flecainide at CV only 778 (10,16%) 34 (4,37%) 266 (34,19%) 9 (1,16%) 469 (60,28%) 
Propafenone at CV only 14 (0,14%) 4 (28,57%) 9 (64,29%) 1 (5,26%) 0 (0%) 
Amiodarone at CV only 65 (0,85%) 18 (27,69%) 34 (52,31%) 1 (1,54%) 12 (18,46%) 
Digoxin at CV only 282 (3,68) 12 (4,26%) 237 (84,04%) 0 (0%) 33 (11,70%) 
Sotalol at CV only 42 (0,55%) 1 (2,38%) 38 (90,48%) 0 (0%) 3 (7,14%) 
Other BB at CV only 596 (7,77%) 7 (1,17%) 476 (79,87%) 5 (0,84%) 108 (18,12%) 
Table 7: Frequency of PCV success using AADs at cardioversion but not at patient discharge 
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However, as seen in table 7 for propafenone, amiodarone, digoxin and the beta blockers, this 
assumption seems not to pan out. Considering the clinical usage profile of these drugs, this is 
no surprise.  Given all options, amiodarone is seldom used to attempt pharmacological CV, 
except in patients with pre-existing significant heart disease. It is also quite possible that 
some cases recorded as used at CV only simply reflects that the patient’s regular amiodarone 
medication was terminated during the treatment episode. As beta blockers and digoxin are 
not used to attempt CV in a hospital setting, as they are not effective at it, it is similarly not 
surprising to see that these drugs are heavily weighted towards ECV. Propafenone usage is 
minimal, owing to flecainide being the favored class 1c drug, and similarly other alternatives 
are preferred over sotalol for attempting pharmacological CV. It is possible that data for 
vernakalant and ibutilide, if available, would display a similar distribution to that observed for 
flecainide, as they are used primarily for attempting CV. 
All in all, this dataset offers little opportunity to evaluate the efficacy of AADs for CV, due to 
the nature of the data collection methodology. 
6 Summary 
To summarize, AF is rapidly becoming more prevalent due to several factors, including the 
aging western population structure and our increasingly sedentary lifestyle. Many risk factors 
are preventable by either lifestyle choices and/or treatment of the specific risk factors. AF 
tends to progress over time from intermittent to permanent, but the risk of recurrence can be 
minimized by treating risk factors, using pharmacological treatment, i.e. rhythm control 
medication, electrophysiological intervention or as a last resort, surgery. Proper 
anticoagulation is paramount in reducing the risk of thromboembolic complications.  
 
So far, no treatment has been shown to be superior to rate control, although striving to 
maintain sinus rhythm is preferential in some situations. In the acute phase this is done by CV, 
often performed by anesthesia and synchronized defibrillation, but several pharmacological 
options are available. While beta blockers primarily improve rate control, sotalol may have 
some efficacy for CV owing to its class 3 properties. Digoxin lacks efficacy in CV, and so far 
there is no evidence supporting that dronedarone would be superior to placebo. 
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Amiodarone on the other hand, though slow and harrowed by the risk of toxicity, reaches an 
efficacy of 62-87% after 24 hours. Flecainide on the other hand, reaches a similar efficacy 
already after a few hours, and propafenone, although much less used, is rather similar, and 
both have the benefit of being suitable for a pill-in-the-pocket approach once safety has been 
established. In an ER/ICU setting, ibutilide excels at cardioverting atrial flutter, either as 
pharmacological CV or infused between ECV attempts, but carries significant TdP risk. The 
most recent AAD, vernakalant, comes with few side effects and swift action, and is similar in 
efficacy to amiodarone, flecainide. 
The FinCV study has provided several new findings regarding the need for anticoagulation 
during CV of acute AF, and the existence of stratified risk also within the first 48 hours. While 
the study design cannot say much about the efficacy of the different AADs in CV, flecainide 
seems have a CV efficacy of at least 60% in this dataset, while ECV remains the gold standard 
with an overall 94% efficacy in this dataset. 
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8 Abbreviations used 
AAD Antiarrhythmic drug 
AF  Atrial fibrillation 
CCG Current Care Guideline 
CV Cardioversion 
ECV Electric cardioversion 
EHRA European Heart Rhythm Association 
ESC European Society of Cardiology 
TdP Torsades de Pointes 
TEC Thromboembolic complication 
WPW Wolff-Parkinson-White syndrome 
